Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Favourable analyst view
About
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole...
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'expensive' on P/E, neutral on EV/EBITDA, rea
Target Price
The average target price of FLGT is 35 and suggests 48% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell